SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 29.87-0.2%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (10496)6/17/1999 11:19:00 AM
From: aknahow  Read Replies (1) of 17367
 
From XOMA old FAQ:

"
Why is the trial so large? How long will it take to enroll patients? updated 3/5/98.
To be conservative, we assumed a slightly less favorable benefit to treated patients than we saw
in Phase II, and have therefore powered the study to 90% certainty to maximize our chances of
demonstrating efficacy. We expect the trial to take about 2 years in 30-40 study centers. "

<<<<<<<we assumed a slightly less favorable benefit to treated patients >>>>>>>>

O.K. so they designed the trial to 90% certainty even with less benefit than shown in P II. Where are we if the same benefit is shown?? Cacaito with 900 patients and the same benefit as in P II is 90% certainty reached????

Any doctors with trauma patients that have ben told enrollments not being accepted please post.

Not saying the trial is over. Just trying to determine if it could be. No, just trying to determine if it is. However, I se no motive for XOMA to conceal the conclusion of this trial. No upside from not telling everyone at once.

But remember we do not know for certain when the Meningo trial ended. We know the end was announced on 14 May. The end had to come before as one must wind down such an important trial at the centers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News